TSL2109 is a selective DYRK2 and CDK4/6 inhibitor, exhibiting an IC50 of 22 nM for DYRK2. This compound induces cell cycle arrest and apoptosis in vitro, effectively suppressing tumor growth in the context of Enzalutamide resistance. TSL2109 demonstrates a safety profile suitable for research applications in prostate and breast cancer studies, highlighting its potential as a therapeutic agent in oncology.
TSL2109 is a selective DYRK2 and CDK4/6 inhibitor, exhibiting an IC50 of 22 nM for DYRK2. This compound induces cell cycle arrest and apoptosis in vitro, effectively suppressing tumor growth in the context of Enzalutamide resistance. TSL2109 demonstrates a safety profile suitable for research applications in prostate and breast cancer studies, highlighting its potential as a therapeutic agent in oncology.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
